Literature DB >> 11266244

Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.

.   

Abstract

Staphylococcus aureus is one of the most common causes of hospital- and community-acquired infections. Nosocomial methicillin-resistant S. aureus (MRSA) infections have become common, and cases of community-acquired MRSA infections also have occurred. Since 1996, vancomycin-intermediate S. aureus (VISA; vancomycin minimum inhibitory concentration [MIC = 8-16 microg/mL) has been identified in Europe, Asia, and the United States. The emergence of reduced vancomycin susceptibility in S. aureus increases the possibility that some strains will become fully resistant and that available antimicrobial agents will become ineffective for treating infections caused by such strains. This report describes the fourth case of confirmed VISA from a patient in the United States.

Entities:  

Mesh:

Year:  2000        PMID: 11266244

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  21 in total

1.  Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.

Authors:  Y Ike; Y Arakawa; X Ma; K Tatewaki; M Nagasawa; H Tomita; K Tanimoto; S Fujimoto
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

2.  Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin.

Authors:  Susan Boyle-Vavra; Shaohui Yin; Mamatha Challapalli; Robert S Daum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

3.  Gram-Positive Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

4.  Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance.

Authors:  Susan Boyle-Vavra; Mamatha Challapalli; Robert S Daum
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 5.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II.

Authors:  Isabelle Verdier; Marie-Elisabeth Reverdy; Jerome Etienne; Gérard Lina; Michèle Bes; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

7.  VISA, hetero-VISA and VRSA: the end of the vancomycin era?

Authors:  John M Conly; B Lynn Johnston
Journal:  Can J Infect Dis       Date:  2002-09

Review 8.  Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.

Authors:  M H Kollef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

9.  Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin.

Authors:  Emmanuel Mongodin; Jon Finan; Michael W Climo; Adriana Rosato; Steven Gill; Gordon L Archer
Journal:  J Bacteriol       Date:  2003-08       Impact factor: 3.490

10.  Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment.

Authors:  Jon-David Schwalm; Philippe El-Helou; Christine H Lee
Journal:  Can J Infect Dis       Date:  2004-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.